CLGN vs. INO, RCEL, OBIO, ZJYL, SPAI, NSPR, FONR, EDAP, HYPR, and BDMD
Should you be buying CollPlant Biotechnologies stock or one of its competitors? The main competitors of CollPlant Biotechnologies include Inovio Pharmaceuticals (INO), Avita Medical (RCEL), Orchestra BioMed (OBIO), Jin Medical International (ZJYL), Safe Pro Group (SPAI), InspireMD (NSPR), Fonar (FONR), Edap Tms (EDAP), Hyperfine (HYPR), and Baird Medical Investment (BDMD). These companies are all part of the "medical equipment" industry.
CollPlant Biotechnologies vs. Its Competitors
Inovio Pharmaceuticals (NASDAQ:INO) and CollPlant Biotechnologies (NASDAQ:CLGN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.
In the previous week, Inovio Pharmaceuticals had 3 more articles in the media than CollPlant Biotechnologies. MarketBeat recorded 5 mentions for Inovio Pharmaceuticals and 2 mentions for CollPlant Biotechnologies. CollPlant Biotechnologies' average media sentiment score of 0.00 beat Inovio Pharmaceuticals' score of -0.02 indicating that CollPlant Biotechnologies is being referred to more favorably in the news media.
CollPlant Biotechnologies has higher revenue and earnings than Inovio Pharmaceuticals. CollPlant Biotechnologies is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Inovio Pharmaceuticals has a net margin of 0.00% compared to CollPlant Biotechnologies' net margin of -541.34%. CollPlant Biotechnologies' return on equity of -94.08% beat Inovio Pharmaceuticals' return on equity.
Inovio Pharmaceuticals has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500. Comparatively, CollPlant Biotechnologies has a beta of 1.61, suggesting that its share price is 61% more volatile than the S&P 500.
26.8% of Inovio Pharmaceuticals shares are held by institutional investors. Comparatively, 21.7% of CollPlant Biotechnologies shares are held by institutional investors. 2.3% of Inovio Pharmaceuticals shares are held by insiders. Comparatively, 9.6% of CollPlant Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Inovio Pharmaceuticals currently has a consensus target price of $8.80, indicating a potential upside of 233.33%. CollPlant Biotechnologies has a consensus target price of $11.50, indicating a potential upside of 322.79%. Given CollPlant Biotechnologies' stronger consensus rating and higher possible upside, analysts plainly believe CollPlant Biotechnologies is more favorable than Inovio Pharmaceuticals.
Summary
CollPlant Biotechnologies beats Inovio Pharmaceuticals on 9 of the 16 factors compared between the two stocks.
Get CollPlant Biotechnologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLGN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CLGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CollPlant Biotechnologies Competitors List
Related Companies and Tools
This page (NASDAQ:CLGN) was last updated on 9/10/2025 by MarketBeat.com Staff
